Esperion Therapeutics Stock Performance
| ESPR Stock | USD 3.43 0.03 0.88% |
On a scale of 0 to 100, Esperion Therapeutics holds a performance score of 7. The firm shows a Beta (market volatility) of 2.56, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Esperion Therapeutics will likely underperform. Please check Esperion Therapeutics' value at risk, as well as the relationship between the kurtosis and market facilitation index , to make a quick decision on whether Esperion Therapeutics' price patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Esperion Therapeutics are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, Esperion Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 82.2 M | |
| Total Cashflows From Investing Activities | -317 K |
Esperion Therapeutics Relative Risk vs. Return Landscape
If you would invest 282.00 in Esperion Therapeutics on November 16, 2025 and sell it today you would earn a total of 61.00 from holding Esperion Therapeutics or generate 21.63% return on investment over 90 days. Esperion Therapeutics is currently generating 0.4113% in daily expected returns and assumes 4.3099% risk (volatility on return distribution) over the 90 days horizon. In different words, 38% of stocks are less volatile than Esperion, and 92% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Esperion Therapeutics Target Price Odds to finish over Current Price
The tendency of Esperion Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 3.43 | 90 days | 3.43 | about 62.33 |
Based on a normal probability distribution, the odds of Esperion Therapeutics to move above the current price in 90 days from now is about 62.33 (This Esperion Therapeutics probability density function shows the probability of Esperion Stock to fall within a particular range of prices over 90 days) .
Esperion Therapeutics Price Density |
| Price |
Predictive Modules for Esperion Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Esperion Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Esperion Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Esperion Therapeutics is not an exception. The market had few large corrections towards the Esperion Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Esperion Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Esperion Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.25 | |
β | Beta against Dow Jones | 2.56 | |
σ | Overall volatility | 0.35 | |
Ir | Information ratio | 0.08 |
Esperion Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Esperion Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Esperion Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Esperion Therapeutics had very high historical volatility over the last 90 days | |
| Esperion Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 332.31 M. Net Loss for the year was (51.74 M) with profit before overhead, payroll, taxes, and interest of 131.9 M. | |
| Esperion Therapeutics currently holds about 185.84 M in cash with (23.65 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.79. | |
| Esperion Therapeutics has a frail financial position based on the latest SEC disclosures |
Esperion Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Esperion Stock often depends not only on the future outlook of the current and potential Esperion Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Esperion Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 187.2 M | |
| Cash And Short Term Investments | 144.8 M |
Esperion Therapeutics Fundamentals Growth
Esperion Stock prices reflect investors' perceptions of the future prospects and financial health of Esperion Therapeutics, and Esperion Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Esperion Stock performance.
| Return On Equity | -2.61 | ||||
| Return On Asset | -0.0542 | ||||
| Profit Margin | (0.35) % | ||||
| Operating Margin | (0.11) % | ||||
| Current Valuation | 1.03 B | ||||
| Shares Outstanding | 239.06 M | ||||
| Price To Earning | (8.19) X | ||||
| Price To Book | 98.42 X | ||||
| Price To Sales | 2.68 X | ||||
| Revenue | 332.31 M | ||||
| EBITDA | 7.57 M | ||||
| Cash And Equivalents | 185.84 M | ||||
| Cash Per Share | 2.79 X | ||||
| Total Debt | 591.21 M | ||||
| Book Value Per Share | (2.20) X | ||||
| Cash Flow From Operations | (23.65 M) | ||||
| Earnings Per Share | (0.54) X | ||||
| Total Asset | 343.82 M | ||||
| Retained Earnings | (1.6 B) | ||||
| Current Asset | 214.39 M | ||||
| Current Liabilities | 5.62 M | ||||
About Esperion Therapeutics Performance
Assessing Esperion Therapeutics' fundamental ratios provides investors with valuable insights into Esperion Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Esperion Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan. Esperion Theraptc operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 218 people.Things to note about Esperion Therapeutics performance evaluation
Checking the ongoing alerts about Esperion Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Esperion Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Esperion Therapeutics had very high historical volatility over the last 90 days | |
| Esperion Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 332.31 M. Net Loss for the year was (51.74 M) with profit before overhead, payroll, taxes, and interest of 131.9 M. | |
| Esperion Therapeutics currently holds about 185.84 M in cash with (23.65 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.79. | |
| Esperion Therapeutics has a frail financial position based on the latest SEC disclosures |
- Analyzing Esperion Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Esperion Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Esperion Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Esperion Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Esperion Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Esperion Therapeutics' stock. These opinions can provide insight into Esperion Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Esperion Stock Analysis
When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.